Core Insights - Whitehawk Therapeutics, Inc. is focused on oncology therapeutics, utilizing advanced technologies to enhance antibody drug conjugate (ADC) cancer treatments [1][3] - The company will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 12:30 PM ET [1] - A live webcast of the discussion will be available on the company's investor relations website and can be replayed for approximately 30 days [2] Company Overview - Whitehawk Therapeutics specializes in oncology therapeutics, applying advanced technologies to established tumor biology for improved cancer treatment delivery [3] - The company has developed a three-asset ADC portfolio designed to address the limitations of first-generation ADCs, aiming to significantly impact patients with difficult-to-treat cancers [3] - These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement [3]

Core Viewpoint - Whitehawk Therapeutics, Inc. is set to present at the Jefferies Global Healthcare Conference, highlighting its focus on advanced oncology therapeutics and antibody drug conjugate (ADC) cancer treatments [1][2]. Company Overview - Whitehawk Therapeutics specializes in oncology therapeutics, utilizing advanced technologies to enhance established tumor biology for improved cancer treatment delivery [3]. - The company has developed a three-asset ADC portfolio designed to address the limitations of first-generation ADCs, aiming to significantly benefit patients with challenging cancers [3]. - These ADC assets are exclusively licensed from WuXi Biologics, covering development and global commercialization [3].